Completed PHASE2 INTERVENTIONAL NCT00143949

Renin Angiotensin System Study (RASS/B-RASS)

Renin Angiotensin System Blockage-DN (RASS)

Sponsor: Canadian Institutes of Health Research (CIHR)

Updated 8 times since 2017 Last updated: Nov 5, 2008 Started: Mar 31, 1997 Primary completion: Mar 31, 2007 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Type 1 Diabetes and is currently completed. Canadian Institutes of Health Research (CIHR) leads this study, which shows 8 recorded versions since 1997 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2022 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canadian Institutes of Health Research (CIHR)
Merck Frosst Canada Ltd.
Merck Sharp & Dohme LLC
Michael Mauer, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada
• Toronto, Canada